Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at UBS Group AG from $20.00 to $19.00. They now have a "buy" rating on the stock.
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated [Yahoo! Finance]
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $20.00 to $19.00. They now have an "overweight" rating on the stock.